All News

Morphea,crop

Increasing Incidence of Morphea

d Jack Cush, MD

A large EMR derived cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on its prevalence and associated features.

Read Article
price%20of%20pills.jpg

ACR Speaks Against Repeated Cuts to Medicare Reimbursements

d ACR

The American College of Rheumatology has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheumatologists and rheumatology interprofessional team members’ ability to provide care to the 53 million Americans living with rheumatic disease.

Read Article
pregnancy,embryo,fetal

Low Placental Transfer Rates with Risankizumab

d Jack Cush, MD

There are significant concerns about the safety of drug use during pregnancy and lactation, especially newer biologic agents. This is complicated by a lack of research. 

Read Article
ACR, guidance, guidelines

ACR Recommends QOL Self-Management Strategies

d ACR

American College of Rheumatology (ACR) experts identified research suggesting that patient self-management is not a

Read Article
Methotrexate

Consensus Guidelines on Pediatric Methotrexate Use

d Jack Cush, MD

Methotrexate (MTX) is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects.

Read Article
Hand%20squeeze.jpg

Moving Forward on RA Prevention Trials

d Jack Cush, MD

Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess interventions that may alter disease development.

Read Article
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush RheumNow ( View Tweet)
Consensus Guidelines on Pediatric Methotrexate Use MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects: -indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF
Dr. John Cush RheumNow ( View Tweet)
UK Biobank study of 34209 pts w/ Abdominal MRIs found a dose response assoc. between visceral & subcutaneous fat and chronic MSK pain, moreso in women. Is adiposity causal or casual in the pathogenesis of chronic pain? https://t.co/w4ziJf7FQD https://t.co/SyUfCPOnHX

Links:

Dr. John Cush RheumNow ( View Tweet)
Wales registry of primary Unilateral knee replacements (UKRs) for #OA (n 106,206) found no outcome differences based on level of training (15 yr UKR failure rates equal for Trainees/16.4% vs Consultants/17.13% https://t.co/uIo4Sv8Lfu https://t.co/LEMrf3vHaR

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA: Switch or Cycle, the Eternal Question Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria. https://t.co/xP65pw5zCw https://t.co/T0nBO3HMIP

Links:

Dr. John Cush RheumNow ( View Tweet)
A low risk of Candida infections with ixekizumab (IXE); integrated analysis of 25; Candida infx rates - PsO:1.9/100 PY (N  6892); PsA 2.0/100 PY (N 1401); axSpA 1.2/100PY (N 932). Most occured only once, were mild/moderate & were oral or genital Candida https://t.co/ZkkPoSzPMW https://t.co/VysnaQ8rpi

Links:

Dr. John Cush RheumNow ( View Tweet)
In elderly onset rheumatoid arthritis, Treg cells are increased, but have decr suppressor activity. Maybe due to elevated Type I IFN with IFN-β suppressing old Tregs and increasing PD-1 expression. https://t.co/51ww481FkJ https://t.co/8EA1fENaFm

Links:

Dr. John Cush RheumNow ( View Tweet)
CA-125 & PET/CT screening in 1432 myositis. 125 pts had CA-125 w/in 5yrs of onset - 3.1% false-positives (fibroids, endometriosis) & 14.3% false-negatives. 139 had PET done- 5.5% false-positives (LN, lung nodules), 28.6% false-negatives (missed melanoma, breast or prostate CA)… https://t.co/16KSDmp9Kz https://t.co/6QFl4jhDxp
Dr. John Cush RheumNow ( View Tweet)
French retrospective study of 181 hemodialysis pts (97 on urate Rx-90% allopurinol, 9% febuxostat). W/ ULT pts had significantly fewer agout flare (HR:0.42; CI 95: 0.25-0.71). Overall flares 35% (23% ULT vs 50% w/o ULT; p 0.0002) https://t.co/9hTgsR2Kx9 https://t.co/Bef0T1po2c

Links:

Dr. John Cush RheumNow ( View Tweet)
Linger on the Fingers (9.6.2024) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. This week with a focus on fingers and better prescriptive follow through. https://t.co/c9yvRjE9av https://t.co/mdN37AWHjX

Links:

Dr. John Cush RheumNow ( View Tweet)
Claims analysis of two datasets showed TNFi treatment in 1st two years after newly Dx breast cancer (n 2216) had no effect on overall survival (OS); but had signif better breast cancer survival (HR 0.28; 0.08–0.98) vs csDMARD Rx. Pts on GC worse OS (HR 2.18)… https://t.co/Kxk7Sy7ahi https://t.co/PtxRsTifi1
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4432 pt COLCORONA trial, showed colchicine had few drug interactions, none serious. The most common were interactions w/ rosuvastatin & atorvastatin (10-12% of all pts), that MAY nonsignificantly increase colchicine exposure https://t.co/W3JXne0ywH https://t.co/dNz6NVYjUW

Links:

Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/givt90C0tE https://t.co/3oN5qUHpUU

Links:

Dr. John Cush RheumNow ( View Tweet)
CAR-T Like Effects with Bispecific Teclistamab A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody… https://t.co/uE7QEHc0nx https://t.co/UcenZHv35O
Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×